FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
June 15th 2023Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.
Read More
FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
June 12th 2023Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.
Read More
Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research
June 8th 2023Dr Holowatyj discusses symptoms associated with appendix cancer, challenges related to understanding the incidence and risk factors of this disease, and ongoing research regarding potential genetic links to this rare cancer.
Read More
Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology
June 5th 2023Dr Raskin discusses the road from fellow to fellowship director at Massachusetts General Hospital, the importance of transparency in a program amid increasing emphasis on health and wellness, and the skills a successful program should impart on their trainees.
Read More
Camidge and Weickhardt Consider Oncology Practice and Patient Care From an International Perspective
June 1st 2023In this episode of How This Is Building Me, Drs Camidge and Weickhardt discuss the span of countries Dr Weickhardt’s medical training and career has led him to, the ins and outs of becoming a practicing oncologist in Australia vs the United States, and the importance of discerning patient needs and preferences to earn patient trust and deliver effective, personalized care across the globe.
Read More
Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML
May 29th 2023Dr Andreeff discusses the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia, the rationale for targeting E-selectin in patients with this disease, how uproleselan could amplify the effects of chemotherapy in the treatment of these patients.
Read More
Gottschalk and Krenciute Discuss the Development of CAR T-cell Therapy in Pediatric Solid Tumors
May 25th 2023Drs Gottschalk and Krenciute discuss the difficulties of translating successes with CAR T-cell therapy in adults to the pediatric population; ongoing research with investigational products that could reduce T-cell exhaustion, burnout, and the time from bench to bedside; and expectations for the future of cellular therapy in oncology.
Read More
Mutale Discusses Disparities in Cancer Clinical Trial Eligibility, Access and Enrollment
May 22nd 2023Dr Mutale discusses common factors contributing to decreased access to cancer clinical trials, how trial enrollment criteria can affect which groups of patients are underrepresented in these trials, and steps that researchers and clinicians can take to increase diversity in clinical trials and mitigate these disparities.
Read More
Oncology Professionals Explain the Nuances of Career-Building Mentorship and Self-Advocacy
May 18th 2023Drs Kovacic, Shaughnessy, Starnes, and Waltz highlight the differences in work culture from their early careers to now, gender-related challenges that persist in medicine today, and advice to incoming medical professionals.
Read More
FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant
May 15th 2023Dr Horwitz discusses the FDA approval of omidubicel in patients with blood cancers, key efficacy and safety data from the pivotal phase 3 trial, and the benefits omidubicel provides beyond improved neutrophil engraftment.
Read More
Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate
May 11th 2023Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.
Read More
Camidge and Turner Reflect on the Importance of Care and Connection Throughout the Cancer Journey
May 4th 2023In today’s episode of ‘How This is Building Me,’ Dr Camidge and Melissa Turner reflect on the bond they share as oncologist and patient, the nuances of Melissa’s transition to hospice care, and the importance of authentically framing her cancer narrative as one where challenges, grief, and gratitude can coexist.
Read More
Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer
April 27th 2023Dr Kim discusses the evaluation of LP-300 for the treatment of patients with advanced lung adenocarcinoma, the rationale for exploring this agent in combination with chemotherapy, and the ongoing HARMONIC trial investigating the combination of LP-300 plus carboplatin and pemetrexed.
Read More
FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
April 24th 2023Dr Friedlander discusses the FDA approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma, key efficacy and safety data from the EV-103 trial, and the importance of incorporating this regimen into the frontline setting for this population.
Read More
Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer
April 20th 2023Drs Gushchin and Diaz-Montes discuss findings from the HOT trial evaluating health-related quality of life outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary ovarian cancer.
Read More
Desai Discusses the Significance of a Supportive, Foundational Fellowship Experience
April 17th 2023Dr Desai discusses the aspects of his oncology fellowship experience that have had the greatest influence on his career growth, the role of mentorship throughout his fellowship and transition to a full-time faculty position, and his advice for current and future oncology fellows.
Read More
Risk Classification, Mutational Analysis Are Key in Informing AML Management
April 14th 2023During an OncLive® workshop titled Key Updates in the Management of Acute Myeloid Leukemia and Their Application in Clinical Practice, moderated by Naval Daver, MD, faculty reviewed updates to the classification of acute myeloid leukemia and its effects on the treatment paradigm and provided insight on the management of adverse-risk and secondary acute myeloid leukemia.
Read More
Drs Mercado and Kovacs discuss the importance of multidisciplinary approaches to lung cancer screening and management, barriers to lung cancer screening that affect how early certain patients are diagnosed with this disease, and where the future of lung cancer detection and treatment is headed.
Read More
Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer
April 3rd 2023Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.
Read More
FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer
March 30th 2023Dr Bidard discusses the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, key efficacy and safety data from the EMERALD trial, and the importance of testing for ESR1 mutations in patients with ER-positive, HER2-negative disease.
Read More
Camidge and Jalal on Setting up an Infrastructure for Success in Life and Work
March 23rd 2023In this episode of ‘How This is Building Me,’ Camidge sits down with Jalal to discuss her transition from life in Jordan to Indianapolis, Indiana, the realities of being a mother in medicine, the importance of transparency in academia, and more.
Read More
FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer
March 20th 2023Dr Tolaney discusses the FDA approval of sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer; key data from the TROPiCS-02 trial; and how this agent can fulfill unmet needs for this patient population.
Read More
Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC
March 16th 2023Dr Raez discusses findings from a study of patients with newly diagnosed non–small cell lung cancer who received both liquid and tissue biopsy, the benefits of liquid biopsy’s relatively short turnaround time, and financial barriers to conducting multiple next-generation sequencing tests per patient.
Read More
FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC
March 9th 2023Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.
Read More